New drug PLX038 targets aggressive brain tumors
NCT ID NCT06161519
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 7 times
Summary
This study tests a drug called PLX038 in adults with brain or spinal cord tumors, including those with changes in the MYC or MYCN genes. The trial has two phases: first, finding the right dose, then checking if it works. Participants receive PLX038 intravenously every three weeks for up to 7 months, with follow-up for up to 5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PLX038
- What this could lead to
- If successful, this could provide a new treatment option for certain brain and spinal cord tumors, especially those with MYC or MYCN gene changes.
- What could go wrong
- This is an early-phase trial (Phase I/II) with a small number of participants, so the drug may not prove effective or safe for wider use. Side effects and risks are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPENDYMOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- Can the Body's own immune cells beat a recurrent brain tumor?
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?